Resistance to chemotherapy represents a major obstacle to the successful 35 treatment of non-small cell lung cancer (NSCLC). The goal of this study was to determine 36 how PIM kinases impact mitochondrial dynamics, ROS production, and response to 37 chemotherapy in lung cancer. Live cell imaging and microscopy were used to determine 
the mitochondrial outer membrane (13, 14) , where it colocalizes with receptors (15). Drp1 
98
However, the mechanism by which PIM inhibition produces excessive ROS is not well 99 understood. Here, we investigate the consequence of altered PIM kinase expression or 100 activity on mitochondrial dynamics, ROS and therapeutic resistance in lung cancer. (Fig 1D) . These, findings suggest that PIM1 upregulation 119 is involved in lung cancer pathogenesis and is significantly associated with resistance to 120 chemotherapy in NSCLC patients. 
122

PIM1 inhibition augments mitochondrial superoxide production and ROS
132
displayed significantly reduced superoxide (Fig 2A) . Similarly, treatment of WT MEFs with 133 a pan-PIM kinase inhibitor (PIM447) caused a 2-fold amplification in superoxide 134 production (Fig 2B) . To validate that the observed effects are specific to inhibition of PIM
135
and not an artifact of the drug itself, we treated a panel of NSCLC cell lines (H1299, A549,
136
and H460) with a chemically distinct pan-PIM kinase inhibitor (AZD1208). A similar 137 induction in superoxide production was observed in response to AZD1208 in all cell lines 138 tested, indicating that these effects are specific to PIM inhibition ( Fig 2C) (Fig 3A-C) . Reintroduction of PIM1 to TKO MEFs restored mitochondria to a 158 more elongated state (>1.5 μm), similar to that observed in WT MEFs (Fig 3A-C) 
164
indicating that PIM regulates mitochondrial phenotype a broad range of cancers (Fig. S2 ).
165
The changes in mitochondrial phenotype observed in response to PIM inhibition were 166 further validated using transmission electron microscopy (TEM) in H1299 lung cancer cells 
169
response to pharmacological inhibition of PIM (Fig 3G-I 
212
Activation of Drp1 via phosphorylation is known to regulate its localization to 213 mitochondria, so we reasoned that loss of PIM would increase the localization of DRP1 to 214 mitochondria. To this end, we used confocal microscopy to assess the co-localization of
215
Drp1 and mitochondria in WT and TKO MEFs. MEFs lacking PIM displayed a significant 216 increase in TOM20 and Drp1 co-localization compared to WT MEFs ( Fig 4H) . Importantly,
217
addback of PIM1 was sufficient to reduce total Drp1 levels as well as its localization to 218 mitochondria, supporting the elongated phenotype observed in these cells (Fig 3B) . Taken 
252
To determine how PIM1 inhibition sensitizes lung cancer cells to docetaxel, we 253 assessed markers related to mitochondrial phenotype and apoptotic cell death. (Fig 5G and 5H) . (Fig 6E) . Importantly, combination therapy significantly increased Drp1 levels 289 compared to AZD1208 alone. Next, tumor tissues (n = 3 tumors/group) were lysed, and
290
immunoblotting was used to assess changes in Drp1 levels and phosphorylation status.
291
PIM inhibition alone or in combination with docetaxel, increased Drp1 phosphorylation at
292
S616 and decreased Drp1 phosphorylation at S637 (Fig 6F) . Moreover, total levels of
293
Drp1 and CC3 were significantly increased in combination-treated tumors. To confirm that
294
PIM inhibition caused mitochondrial fragmentation in vivo, tumor tissues from control or
295
AZD1208-treated mice were processed and imaged by TEM. Significantly more
296
fragmented mitochondria were present in the AZD1208-treated tumors than the control 297 tumors (Fig 6G) . Quantification revealed that the average mitochondrial length in tumors
298
was reduced from 1.1μm to 0.6 μm with PIM inhibition (Fig 6H) . response to chemotherapy than patients with low PIM1 (Fig 1B) . 
427
Then, cells were washed with 1X DPBS and associated staining was determined either 428 on mounted slides or in live cells using fluorescent microscopy. 
440
Sample temperature was stabilized and kept at 37°C by the Temperature & Gas Controller
441
"Bio III" unit, interfaced to the spectrometer. Spectra were recorded and analyzed by using
442
Win EPR software (2.11 version). ROS was also measured by DCF staining, as described 443 previously (20).
445
Immunofluorescence: Cells were plated in 6-well plates containing microscope 
474
The cells were lysed in a 1% sodium dodecyl sulfate solution, and absorbance was 
